Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women

Lipids in Health and Disease

Bhagu R Bhavnani¹  Alan Gerulath¹  Anthony Cecutti¹  Mauricio Berco¹  Joel Perrella¹ 

[1] Department of Obstetrics and Gynecology Institute of Medical Sciences, University of Toronto and St. Michael's Hospital, Toronto, Ontario, CANADA – M5B 1W8

关键词: Alzheimer's disease;    lag time;    conjugated dienes;    antioxidants;    postmenopausal women;    oxidized LDL;    oxidized HDL;    coronary heart disease;    neurodegenerative diseases;   

Others  :  1213325
DOI  :  10.1186/1476-511X-2-4

 received in 2003-05-21, accepted in 2003-06-20,  发布年份 2003

【 摘 要 】

Background

An inverse relationship between the level of high-density lipoprotein (HDL) and coronary heart disease (CHD) has been reported. In contrast, oxidized HDL (oHDL) has been shown to induce neuronal death and may play an important role in the pathogenesis of CHD. In the present study we have investigated a: the effect of various equine estrogens on HDL oxidation, b: the inhibition of LDL oxidation by HDL and c: the effect of these estrogens on LDL oxidation in the presence of HDL.

Results

All 11 equine estrogens tested protected the HDL from oxidation in a concentration dependant manner. Equilenin, 17β-dihydroequilenin, and 17α-dihydroequilenin (Δ^6–8-estrogens) were found to be the most potent inhibitors of HDL oxidation. Some of the novel ring B unsaturated estrogens were 2.5 to 4 times more potent inhibitors of HDL oxidation than 17β-estradiol. HDL was found to delay LDL oxidation. The protection of LDL oxidation by HDL is enhanced by the addition of estrogen, with equilenin being again more potent than 17β-estradiol.

Conclusions

Equine estrogens can differentially inhibit the oxidation of HDL with the Δ^6–8-estrogens being the most potent antioxidants. The ability of estrogens to enhance HDL's antioxidant activity is to our knowledge the first report of an interaction of estrogen with HDL that results in the delay or inhibition of LDL oxidation. This may be another mechanism by which estrogens may reduce the risk of CHD and neurodegenerative diseases in healthy and younger postmenopausal women.

【 授权许可】

   
2003 Perrella et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
• [2]Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of AD in women. Am J Epidemiol 1994, 140:256-261.
• [3]Draczynska-Lusiak B, Doung A, Sun AY: Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease. Mol Chem Neuropathol 1998, 33:139-148.
• [4]Keller JN, Hanni KB, Markesbery WR: Oxidized low-density lipoprotein induces neuronal death: Implications for calcium, reactive oxygen species and caspases. J Neurochem 1999, 72:2601-2609.
• [5]Sugawa M, Ikeda S, Kushima Y, Takashima Y, Cynshi O: Oxidized low-density lipoprotein causes CNS neuronal cell death. Brain Res 1997, 761:165-172.
• [6]Berliner JA, Territo M, Sevanian A, Ramin S, Kim JA, Ramshad B, Esterson M, Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990, 85:1260-1266.
• [7]Fogelman AM, Shechter I, Saeger J, Hokom M, Child JS, Edwards IA: Malodialdehyde alteration of low-density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980, 77:2214-2218.
• [8]Berco M, Bhavnani BR: Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death. J Soc Gynecol Investig 2001, 8:245-254.
• [9]Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
• [10]Durrington PN: High-density lipoprotein cholesterol: methods and clinical significance. Crit Rev Clin Lab Sci 1982, 18:31-78.
• [11]Bonnefront-Rousselot D, Therond P, Beaudeux JL, Peynet J, Legrand A, Delattre J: High density lipoprotein (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999, 37:939-948.
• [12]Chung BH, Segrest JP, Smith K, Griffin FM, Brouillette CG: Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis? J Clin Invest 1989, 83:1363-1374.
• [13]Ohta T, Takata S, Morino Y, Matesuda I: Protective effect of lipoproteins containing apoprotein A-I on Cu2+-catalyzed oxidation of human low density lipoprotein. FEBS Lett 1989, 257:435-438.
• [14]Parthasarthy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275-283.
• [15]Sangvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M: The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low density lipoprotein. Biochem Biophys Res Comm 2003, 300:501-506.
• [16]Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modifications by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
• [17]Nagano Y, Arai H, Kita T: High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991, 88:6457-6461.
• [18]Ohmura H, Watanabe Y, Hatsumi C, Sato H, Daida H, Mokuno H, Yamagochi H: Possible role of high susceptibility of high-density lipoprotein to lipid peroxidative modifications and oxidized high-density lipoprotein in genesis of coronary artery spasm. Atherosclerosis 1999, 142:179-184.
• [19]Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991, 325:756-762.
• [20]Tikkanen MJ: Sex hormones. In In Lipoproteins in health and disease. Edited by Betterridge J, Illingworth R, Sheperd J. London, England: Hodder and Stoughton Publishers; 1999:967-984.
• [21]Barrett-Conner E, Bush TL: Estrogens and coronary heart disease in women. JAMA 1991, 265:1861-1867.
• [22]Pickar JH, Thorneycroft I, Whitehead M: Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 1998, 178:1087-1099.
• [23]Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z: Antioxidant potential of specific estrogens on lipid peroxidation. JCE & M 1993, 77:1095-1097.
• [24]Bhavnani BR, Cecutti A, Gerulath A, Woolever AC, Berco M: Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause 2001, 8:408-419.
• [25]Esterbauer H, Striegil G, Puhl H, Rothender M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Res Comm 1989, 52:302-310.
• [26]Thomas MJ, Chen Q, Zabalawi M, Anderson R, Wilson R, Weinberg R, M Sorci-Thomas MG, Rude LL: Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? Biochemistry 2001, 40:1719-1724.
• [27]Meng Q, Hockerstedt A, Heinonen S, Wahala K, Adlercreutz H, Tikkanen MJ: Antioxidant protection of lipoproteins containing estrogens: in vitro evidence for low- and high-density lipoproteins as estrogen carriers. Biochim Biophys Acta 1999, 1493:331-40.
• [28]Bhavnani BR, Cecutti A, Gerulath A: Pharmacokinetics and pharmacodynamics of a novel estrogen delta-8-estrone in postmenopausal women and men. J Steriod Biochem Mol Biol 1998, 67:119-131.
• [29]Bhavnani BR, Nisker JA, Martin J, Aletebi F, Watson L, Milne JK: Comparison of pharmacokinetics of a conjugated equine estrogen preparation (Premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Investig 2000, 7:175-183.
• [30]Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F: Neuroprotection against oxidative stress by estrogens – structure activity relationship. Molec Pharm 1997, 51:535-541.
• [31]Green PS, Bishop J, Simpkins JW: 17 alpha-estradiol exerts neuroprotective effects on sk-n-sh cells. J Neurosci 1997, 17:511-515.
• [32]Moosman B, Behl C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999, 96:8867-8872.
• [33]Bhavnani BR, Lu XF: Differential interaction of equine estrogens with recombinant human estrogen receptors alpha (ERα) and beta (ERβ). J Soc Gynecol Investig 2003, 10(suppl):298A (Abstract).
• [34]Bhavnani BR, Woolever CA: Interaction of equine estrogens with estrogen receptors of human and rat uterus. Steroids 1991, 56:201-209.
• [35]Huang J, Huang Z, Zhu W: Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. Clin Biochem 1998, 31:537-543.
• [36]Bowry VW, Stanley KK, Stocker R: High-density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992, 89:10316-10320.
• [37]Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
• [38]Lin KY, Chen YL, Shih CC, Pan JP, Chan WE, Chiang AN: Contribution of HDL-apolipoproteins to the inhibition of low density lipoprotein oxidation and lipid accumulation in macrophages. J Cell Biochem 2002, 86:258-267.
• [39]Zhang X, Jiao J, Bhavnani BR, Tam S: Regulation of human apolipoprotein A-1 gene expression by equine estrogens. J Lipid Res 2001, 42:1789-1800.
• [40]Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T: HDL3 exerts more powerful anti-oxidative, protective effects against copper catalyzed LDL oxidation than HDL2. Clin Biochem 1997, 30:221-225.
• [41]Lacort M, Leal AM, Liza M, Matin C, Martinez R, Ruiz-Larrea MB: Protective effect of estrogens and catechol estrogens against peroxidative membrane damage in vitro. Lipids 1995, 30:141-146.
• [42]Kleinveld HA, Hak-Lemmers HL, Stalenhoof AF, Demacker PN: Improved measurement of low-density lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem 1992, 38:2066-2072.
• [43]Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT: Single vertical spin density gradient ultracentrifugation. Meth Enzymol 1986, 128:181-209.
• [44]Bradford MM: A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976, 72:248-254.
• [45]Noble RP: Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968, 9:693-700.
• [46]Steinbrecher UP: Oxidation of human low density results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987, 262:3603-3608.